scholarly journals Elevated C1orf63 expression is correlated with CDK10 and predicts better outcome for advanced breast cancers: a retrospective study

BMC Cancer ◽  
2015 ◽  
Vol 15 (1) ◽  
Author(s):  
Chao-Qun Hong ◽  
Fan Zhang ◽  
Yan-Jie You ◽  
Wei-Li Qiu ◽  
Armando E. Giuliano ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Advanced Breast ◽  
Breast Cancers

scholarly journals Changes in allelic imbalances in locally advanced breast cancers after chemotherapy

2007 ◽  
Vol 97 (8) ◽  
pp. 1157-1164 ◽  
Author(s):  
M Varna ◽  
H Soliman ◽  
J-P Feugeas ◽  
E Turpin ◽  
D Chapelin ◽  
...  
Keyword(s):  
Locally Advanced ◽  
Advanced Breast ◽  
Breast Cancers

scholarly journals Currently Applied Molecular Assays for Identifying ESR1 Mutations in Patients with Advanced Breast Cancer

2020 ◽  
Vol 21 (22) ◽  
pp. 8807
Author(s):  
Nuri Lee ◽  
Min-Jeong Park ◽  
Wonkeun Song ◽  
Kibum Jeon ◽  
Seri Jeong
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Endocrine Therapy ◽  
High Sensitivity ◽  
Digital Pcr ◽  
Advanced Breast ◽  
Sample Type ◽  
Breast Cancers ◽  
Esr1 Mutations ◽  
Next Generation Sequencing Ngs

Approximately 70% of breast cancers, the leading cause of cancer-related mortality worldwide, are positive for the estrogen receptor (ER). Treatment of patients with luminal subtypes is mainly based on endocrine therapy. However, ER positivity is reduced and ESR1 mutations play an important role in resistance to endocrine therapy, leading to advanced breast cancer. Various methodologies for the detection of ESR1 mutations have been developed, and the most commonly used method is next-generation sequencing (NGS)-based assays (50.0%) followed by droplet digital PCR (ddPCR) (45.5%). Regarding the sample type, tissue (50.0%) was more frequently used than plasma (27.3%). However, plasma (46.2%) became the most used method in 2016–2019, in contrast to 2012–2015 (22.2%). In 2016–2019, ddPCR (61.5%), rather than NGS (30.8%), became a more popular method than it was in 2012–2015. The easy accessibility, non-invasiveness, and demonstrated usefulness with high sensitivity of ddPCR using plasma have changed the trends. When using these assays, there should be a comprehensive understanding of the principles, advantages, vulnerability, and precautions for interpretation. In the future, advanced NGS platforms and modified ddPCR will benefit patients by facilitating treatment decisions efficiently based on information regarding ESR1 mutations.

Molecular Testing in Breast Cancer

2019 ◽  
pp. e1-e7 ◽  
Author(s):  
Jennifer K. Litton ◽  
Harold J. Burstein ◽  
Nicholas C. Turner
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Hereditary Cancer ◽  
Standard Of Care ◽  
Genomic Variation ◽  
Advanced Breast ◽  
Hereditary Cancer Syndrome ◽  
Molecular Testing ◽  
Breast Cancers ◽  
Cancer Management

Molecular testing for genetic and genomic variation has become an integral part of breast cancer management. Patients with a family history of breast cancer or other tumors, bilateral breast cancers, or early-onset breast cancers warrant genetic testing to determine whether a hereditary cancer syndrome is present. The availability of PARP inhibitors—drugs that are selectively active in BRCA1/2-associated breast cancers—has created the need for hereditary cancer testing for all patients diagnosed with advanced breast cancer. Tumor genomic profiling is the standard of care for many types of malignancies and is becoming increasingly important in the management of advanced breast cancer. Targetable mutations in advanced breast cancer include PIK3CA, HER2, and rare instances of mismatch deficiency or other targets for tyrosine kinase inhibitors. The development of methods for sequencing cell-free DNA should allow for broader and easier implementation of tumor genomic testing. Transcriptome-based expression signatures have become the standard of care in the management of early-stage estrogen receptor–positive breast cancers. These assays provide prognostic significance in the setting of adjuvant endocrine therapy and are predictive for benefit from adjuvant chemotherapy. Collectively, these developments underscore the contemporary reality that molecular testing is now part of the clinical management for the majority of patients with breast cancer.

Treatment and Outcomes of Women With Large Locally Advanced Breast Cancer

2020 ◽  
pp. 000313482095633
Author(s):  
Christopher W. Mangieri ◽  
Julia Ruffo ◽  
Akiko Chiba ◽  
Marissa Howard-McNatt
Keyword(s):  
Breast Cancer ◽  
Metastatic Cancer ◽  
Locally Advanced Breast Cancer ◽  
Multidisciplinary Treatment ◽  
Locally Advanced ◽  
Radical Mastectomy ◽  
Advanced Breast ◽  
Breast Cancers ◽  
Social Challenges ◽  
Radiation Treatments

Advances in breast cancer research have made breast cancer a treatable disease. However, there is a population of women who present with large, advanced, or sometimes neglected breast cancers who can prove difficult to treat. These women often require multiple modality treatment including chemotherapy, surgery, and radiation. The purpose of our study is to examine the treatment and outcomes on women with large, locally advanced breast cancers (LABCs). We identified 8 individuals who presented with LABCs requiring extensive treatment. Patients with inflammatory or metastatic cancer at the time of presentation were excluded. These patients’ charts were reviewed and analyzed. Patient demographics, hormone receptor status, stage, types of treatment, presence of metastasis, survival, and presence of barriers for seeking treatment sooner were identified. The median age at presentation was 65 years old. The patients were equally African American and Caucasian. All patients presented with T4 or stage 3 tumors involving the skin and/or pectoralis muscle. Half of the patients were found to have triple-negative (estrogen receptor, progesterone receptor, Her-2/neu negative) tumors. 87% of the patients received chemotherapy; 1 refused. All 8 patients, either neoadjuvantly or adjuvantly, underwent a modified radical or radical mastectomy. Skin graft or flap coverage was necessary in half of the patients. Postmastectomy radiation was received in 87% of the patients; 1 patient refused the treatment. Half of the patients developed metastatic disease. Thirty-seven percent of the patients have since died with a median survival of 44 months. Reasons for delay in seeking care were monetary or social barriers. Many of the patients finally sought care via the emergency room due to symptoms they could no longer ignore. Women who present with LABC require complex multidisciplinary treatment consisting of chemotherapy, surgery, and radiation treatments. Many of these patients faced economic and social challenges to accessing care. Better access to care and more prompt connection to breast surgeons are required to assist this patient population.

Hypermethylation analysis of mismatch repair genes (hmlh1 and hmsh2) in locally advanced breast cancers in Indian women

2008 ◽  
Vol 39 (5) ◽  
pp. 672-680 ◽  
Author(s):  
Raza Ali Naqvi ◽  
Arif Hussain ◽  
Suryanarayan S.V. Deo ◽  
Himani Kukreti ◽  
Madhur Chauhan ◽  
...  
Keyword(s):  
Mismatch Repair ◽  
Locally Advanced ◽  
Advanced Breast ◽  
Mismatch Repair Genes ◽  
Breast Cancers ◽  
Indian Women ◽  
Repair Genes

Value and indications of surgery in locally advanced breast cancers

1997 ◽  
Vol 33 ◽  
pp. S216
Author(s):  
C. Nos ◽  
A. Fourquet ◽  
J.M. Cosset ◽  
B. Asselain ◽  
T. Palangie ◽  
...  
Keyword(s):  
Locally Advanced ◽  
Advanced Breast ◽  
Breast Cancers
Sign in / Sign up

Export Citation Format

Share Document